Research-use-only context. This article summarizes published third-party scientific literature — the large majority of it conducted in cultured cells or animal models. It is not medical advice, not a therapeutic or performance claim, and not a usage guide. American Peptides products are sold strictly for in vitro laboratory research and are not for human or veterinary use.
What cagrilintide is, structurally
Cagrilintide — also cataloged as AM833 — is a synthetic analogue of human amylin, the pancreatic islet peptide co-secreted with insulin. Its molecular formula is C194H312N54O59S2 with an average molecular weight of approximately 4409 g/mol, and it carries CAS registry number 1415456-99-3 (PubChem CID 171397054).
The design problem the medicinal-chemistry literature set out to solve is that native amylin is poorly soluble and aggregation-prone, and it clears quickly. A 2021 medicinal chemistry paper documenting the development of cagrilintide describes the approach taken: substitute residues that drive aggregation, and attach a lipid side chain so the peptide reversibly associates with serum albumin.1 That albumin-binding strategy is a well-established tool in peptide chemistry for extending circulating half-life, and it is the structural feature that separates cagrilintide from the parent hormone.
Amylin receptor pharmacology
Amylin does not have a single dedicated receptor. Receptor-pharmacology work describes the amylin receptor family as a set of complexes formed when the calcitonin receptor associates with receptor-activity-modifying proteins — RAMP1, RAMP2 and RAMP3 — producing the AMY1, AMY2 and AMY3 subtypes. Selectivity across those subtypes, and cross-reactivity with the calcitonin receptor itself, is what receptor-binding and functional-assay work on amylin analogues actually measures.
This is in-vitro analytical pharmacology: binding affinities and concentration-response curves generated in cell systems expressing defined receptor complexes. It characterises how a molecule behaves at a receptor. It is not a statement about what happens in an organism.
Where the wider literature sits
Review articles surveying long-acting amylin analogues place cagrilintide within a broader class of agents under investigation, and discuss the pharmacological rationale for combining amylin-receptor and incretin-receptor mechanisms.2 A 2024 clinical-pharmacology review of amylin analogues frames the whole category as an area of active investigation rather than settled science, and is explicit that questions of durability and comparative performance remain open.3
For a researcher, the useful takeaway from those reviews is the framing: this is a class being characterised, not a class that has been characterised.
What the research has not established
The honest summary of the cagrilintide literature is that it is early and largely preclinical. Much of what is published concerns molecular design and receptor-level behaviour rather than long-term biology. Reviewers writing in this area consistently describe the compound as investigational, and it is not approved by the FDA for any use. Findings generated in cultured cells or in animal models do not transfer automatically to any other context, and the gap between a receptor-level observation and a demonstrated outcome in people is the single largest caveat a researcher surveying this literature should carry forward.
Handling notes for laboratory work
Cagrilintide is supplied as a lyophilized powder. As a lipidated peptide it is more surface-active than an unmodified sequence, which in practice means laboratories tend to swirl gently rather than agitate vigorously to limit foaming and adsorption losses at the air-liquid interface. Lyophilized peptide is stored at −20 C, sealed, desiccated and protected from light; solutions are markedly less stable than the dry powder, so aliquoting to avoid repeated freeze-thaw cycles is standard practice. Full specifications are on the cagrilintide reference monograph.
Frequently Asked Questions
What is cagrilintide?
Cagrilintide (AM833) is a synthetic long-acting analogue of human amylin — a 32-residue peptide carrying a lipid side chain that promotes reversible albumin binding. It is supplied as a lyophilized powder for laboratory research use only and is not a drug, food or cosmetic.
What receptors does the amylin literature associate with it?
Published receptor-pharmacology describes the amylin receptor family, formed by the calcitonin receptor in complex with receptor-activity-modifying proteins (RAMP1, RAMP2, RAMP3). That is a description of in-vitro receptor behaviour, not a statement about outcomes in people.
Why does cagrilintide have a lipid side chain?
Medicinal-chemistry literature describes lipidation as a strategy for extending circulating half-life through reversible albumin association, alongside sequence substitutions intended to reduce the aggregation tendency of native amylin.
Is cagrilintide approved by the FDA?
No. It is an investigational compound and is not approved by the FDA for any indication. Material supplied by American Peptides is a research chemical for laboratory use only.
References
- Medicinal chemistry paper documenting the development of cagrilintide as a long-acting amylin analogue. J Med Chem, 2021. PubMed 34288673
- Review of cagrilintide as a long-acting amylin analogue and its pharmacological rationale. Cardiol Rev, 2024. PubMed 36883831
- Clinical-pharmacology review surveying amylin analogues, present status and open questions. Expert Rev Clin Pharmacol, 2024. PubMed 39317404
This article is for laboratory research reference only. American Peptides products are sold strictly for in vitro research. Not for human consumption.
Related research
Compliance Notice: American Peptides products are sold strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution’s safety protocols and applicable laws.
